A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target-based genetic tool.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 12438686.
- Also identified by PMC identifier 137767.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Enhancer DNA decoy oligodeoxynucleotides (ODNs) inhibit transcription by competing for transcription factors. A decoy ODN composed of the cAMP response element (CRE) inhibits CRE-directed gene transcription and tumor growth without affecting normal cell growth. Here, we use DNA microarrays to analyze the global effects of the CRE-decoy ODN in cancer cell lines and in tumors grown in nude mice. The CRE-decoy up-regulates the AP-2beta transcription factor gene in tumors but not in the livers of host animals. The up-regulated expression of AP-2beta is clustered with the up-regulation of other genes involved in development and cell differentiation. Concomitantly, another cluster of genes involved in cell proliferation and transformation is down-regulated. The observed alterations indicate that CRE-directed transcription favors tumor growth. The CRE-decoy ODN, therefore, may serve as a target-based genetic tool to treat cancer and other diseases in which CRE-directed transcription is abnormally used.
Medical subject headings
- Adenocarcinoma
- Cyclic AMP
- Cyclic AMP Response Element-Binding Protein
- Enhancer Elements, Genetic
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Oligodeoxyribonucleotides
- Oligonucleotide Array Sequence Analysis
- Prostatic Neoplasms
- Second Messenger Systems
- Thionucleotides
- Transcription, Genetic